Advancements in SPR biosensing technology: An overview of recent trends in smart layers design, multiplexing concepts, continuous monitoring and in vivo sensing

Qu, Jia-Huan; Dillen, Annelies; Saeys, Wouter; Lammertyn, Jeroen; Spasić, Dragana

doi:10.1016/j.aca.2019.12.067

Cited by 100 publications

(83 citation statements)

References 154 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Many interesting ways exist to achieve the development of an optical fiber sensor for which the most frequently encountered designs include unclad fibers, U-bent fibers [10], etched fibers [11], tapered fibers [12] and fiber gratings [4][5][6][13][14][15]. In these aforementioned configurations, tilted fiber Bragg gratings (TFBGs) represent a particularly convenient and relevant solution for biochemical and/or medical sensing once coupled to surface plasmon resonance (SPR) and bioreceptors immobilization (antibodies, aptamers, enzymes, etc) [16][17][18][19][20]. This refractive index modulation inscribed within the fiber couples light out the core and makes this waveguide sensitive to the outer medium.…”

Section: Introductionmentioning

confidence: 99%

HER2 biosensing through SPR-envelope tracking in plasmonic optical fiber gratings

Lobry¹,

Loyez²,

Chah³

et al. 2020

Biomed. Opt. Express

View full text Add to dashboard Cite

In the biomedical detection context, plasmonic tilted fiber Bragg gratings (TFBGs) have been demonstrated to be a very accurate and sensitive sensing tool, especially well-adapted for biochemical detection. In this work, we have developed an aptasensor following a triple strategy to improve the overall sensing performances and robustness. Single polarization fiber (SPF) is used as biosensor substrate while the demodulation is based on tracking a peculiar feature of the lower envelope of the cladding mode resonances spectrum. This method is highly sensitive and yields wavelength shifts several tens of times higher than the ones reported so far based on the tracking of individual modes of the spectrum. An amplification of the response is further performed through a sandwich assay by the use of specific antibodies. These improvements have been achieved on a biosensor developed for the detection of the HER2 (Human Epidermal Growth Factor Receptor-2) protein, a relevant breast cancer biomarker. These advanced developments can be very interesting for point-of-care biomedical measurements in a convenient practical way.

show abstract

Section: Introductionmentioning

confidence: 99%

HER2 biosensing through SPR-envelope tracking in plasmonic optical fiber gratings

Lobry¹,

Loyez²,

Chah³

et al. 2020

Biomed. Opt. Express

View full text Add to dashboard Cite

show abstract

“…There are other alternative technologies that have great potential to achieve CDM in the near future. In a very recent research from KU Leuven, the researchers carefully discuss the strategies for using label-free surface plasma resonance (SPR) based biosensors to achieve continuous or in vivo monitoring of therapeutic drugs [ 102 ]. Another study on a multisensor-organs-on-chips platform demonstrate its capacity to constantly determine drug concentration and the drug’s effect on human organs (e.g., liver, heart, or brain) along with a simultaneous evaluation of microenvironment parameters (pH, temperature) [ 103 ].…”

Section: Discussionmentioning

confidence: 99%

Towards wearable and implantable continuous drug monitoring: A review

Bian

Zhu

Rong

et al. 2021

Journal of Pharmaceutical Analysis

View full text Add to dashboard Cite

Continuous drug monitoring is a promising alternative to current therapeutic drug monitoring strategies and has strong potential to reshape our understanding of pharmacokinetic variability and to improve individualised therapy. This review highlights recent advances in biosensing technologies that support continuous drug monitoring in real time. We focus primarily on aptamer-based biosensors, wearable and implantable devices. Emphasis is given to the approaches employed in constructing biosensors. We pay attention to sensors’ biocompatibility, calibration performance, long-term characteristics stability and measurement quality. In the end, we discuss about the current challenges and issues to address in continuous drug monitoring to make it a promising, future tool for individualised therapy. The ongoing efforts are expected to result in fully integrated implantable drug biosensing technology. Thus, we may anticipate an era of advanced healthcare in which wearable and implantable biochips automatically adjust drug dosing in response to patient health conditions enabling the management of diseases and enhancing individualised therapy.

show abstract

“…In this sense, several plasmonic-based platforms have utilized low-fouling surfaces to prevent nonspecific adsorption of proteins, cells, lipids and microorganisms from biological samples such as whole blood (plasma or serum), saliva or cell lysates without inhibiting the recognition of analytes and the attachment to biomolecular receptors [34,41]. Since the analytical performance of plasmonic biosensors enables biomarker detection in the nanomolar to picomolar range, antifouling coatings should confer excellent stability and compatibility to the immobilized biological receptor in order to allow analyte recognition at very low concentrations with the sufficient accuracy and sensitivity.…”

Section: Antifouling Surfacesmentioning

confidence: 99%

“…An interesting approach for evaluating the influence of chain densities involves the design of peptoids with equimolar analogs of opposing signs functionalized with thiol groups and grafted onto Au surfaces (~1 pg/mm 2 ) [51]. The application of 3D-structured zwitterionic carboxybetaine thin film hydrogels onto plasmonic sensor chips has also proved its effectiveness for preventing protein fouling or bacterial infections (<5 ng mL −1 of foulants in undiluted serum) [41,52,53].…”

Section: Zwitterionic Compoundsmentioning

confidence: 99%

Low-Fouling Substrates for Plasmonic Sensing of Circulating Biomarkers in Biological Fluids

Mauriz

2020

Biosensors

View full text Add to dashboard Cite

The monitoring of biomarkers in body fluids provides valuable prognostic information regarding disease onset and progression. Most biosensing approaches use noninvasive screening tools and are conducted in order to improve early clinical diagnosis. However, biofouling of the sensing surface may disturb the quantification of circulating biomarkers in complex biological fluids. Thus, there is a great need for antifouling interfaces to be designed in order to reduce nonspecific adsorption and prevent inactivation of biological receptors and loss of sensitivity. To address these limitations and enable their application in clinical practice, a variety of plasmonic platforms have been recently developed for biomarker analysis in easily accessible biological fluids. This review presents an overview of the latest advances in the design of antifouling strategies for the detection of clinically relevant biomarkers on the basis of the characteristics of biological samples. The impact of nanoplasmonic biosensors as point-of-care devices has been examined for a wide range of biomarkers associated with cancer, inflammatory, infectious and neurodegenerative diseases. Clinical applications in readily obtainable biofluids such as blood, saliva, urine, tears and cerebrospinal and synovial fluids, covering almost the whole range of plasmonic applications, from surface plasmon resonance (SPR) to surface-enhanced Raman scattering (SERS), are also discussed.

show abstract

Advancements in SPR biosensing technology: An overview of recent trends in smart layers design, multiplexing concepts, continuous monitoring and in vivo sensing

Cited by 100 publications

References 154 publications

HER2 biosensing through SPR-envelope tracking in plasmonic optical fiber gratings

HER2 biosensing through SPR-envelope tracking in plasmonic optical fiber gratings

Towards wearable and implantable continuous drug monitoring: A review

Low-Fouling Substrates for Plasmonic Sensing of Circulating Biomarkers in Biological Fluids

Contact Info

Product

Resources

About